Urea-based recirculation validation of the symmetrical palindrome catheter.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Jonczyk, M
  • Althoff, C
  • Slowinski, T
  • Lieker, I
  • Naik, M
  • Auer, J
  • Duka, E
  • Hamm, B
  • de Bucourt, M

Grupos

Abstract

BACKGROUND: High blood flow and low recirculation rates are central for adequate haemodialysis. A new symmetrical tip has been invented promising efficient haemodialysis even if the ports are reversed. OBJECTIVE: To evaluate access recirculation of the 'palindrome' catheter and to report initial experiences in a clinical setting. MATERIAL AND METHODS: After implantation of the new catheter in 20 patients (male: 14; female: 6; mean age 72 +/- 12.2), access recirculation was evaluated using the urea-based recirculation test. After 30 minutes of haemodialysis, ultrafiltration was stopped and arterial and venous samples were taken. Afterwards, the blood flow rate was reduced to 120 ml/min. Another systemic arterial blood sample was taken 10 seconds after the blood pump was switched off. RESULTS: All 20 interventions were performed successfully without complications. The average recirculation rate was 8.1% with a median of 2.5% ranging from 0 to 85.8%. Recirculation rates under 5% were measured in 13 patients and more than 10% recirculation were found in two patients. The median of days between catheter implantation and recirculation assessment was the day following implantation. CONCLUSION: The new symmetrical catheter presented low recirculation rates in a clinical setting. Since there is just a single tip, fluoroscopic placement in the right atrium is facilitated.

Datos de la publicación

ISSN/ISSNe:
1755-6678, 1755-6686

Journal Of Renal Care  WILEY

Tipo:
Article
Páginas:
242-246
Factor de Impacto:
0,412 SCImago
Cuartil:
Q2 SCImago

Citas Recibidas en Web of Science: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Central venous access; Haemodialysis catheter; Palindrome; Urea recirculation

Proyectos asociados

HECATOS. HEPATIC AND CARDIAC TOXICITY SYSTEMS MODELLING.

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

602156_HECATOS_PE_FP7-HEALTH-2013-INNOVATI . 2013

DISEÑO Y DESARROLLO DE UNA PLATAFORMA MULTIESCALA-IN VITRO-IN VIVO PARA LA PREVENCIÓN DE LA FRACTURA ÓSEA OSTEOPORÓTICA MEDIANTE CEMENTACIÓN FEMORAL: UNA HERRAMIENTA PRECLÍNICA

Investigador Principal: ÁNGEL ALBERICH BAYARRI

DPI2014-53401-C2-2-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2015

ENSAYO CLINICO EN FASE III, DE "THERASPHERE" INTRAARTERIAL PARA EL TRATAMIENTO DE PACIENTES CON CARCINOMA HEPATOCELULAR(CHC) NO RESECALBE.

Investigador Principal: DANIEL PÉREZ ENGUIX

TS-103 . 2016

ENSAYO CLÍNICO RANDOMIZADO, MULTICÉNTRICO FASE 1B/3 DE TALIMOGENE LAHERPAREPVEC EN COMBINACIÓN CON PEMBROLIZUMAB PARA EL TRATAMIENTO DE PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS DE CABEZA Y CUELLO METASTÁSICO O RECURRENTE.

Investigador Principal: JAVIER CABALLERO DAROQUI

20130232 . 2017

ENSAYO CLÍNICO PROSPECTIVO Y RANDOMIZADO SOBRE EL USO DE LA RADIOEMBOLIZACIÓN TRANSARTERIAL CON ITRIO 90 (THERASPHERE®) FRENTE AL TRATAMIENTO HABITUAL (SORAFENIB), EN EL TRATAMIENTO DE PACIENTES CON CARCINOMA HEPATOCELULAR EN ESTADIO AVANZADO Y TROMBOSIS PORTAL ASOCIADA.

Investigador Principal: DANIEL PÉREZ ENGUIX

TS-104

ESTUDIO DE FASE III, ALEATORIZADO, ABIERTO QUE COMPARA LA COMBINACIÓN DEL INHIBIDOR DE BRAF, (DABRAFENIB) Y EL INHIBIDOR DE MEK (TRAMETINIB), CON EL INHIBIDOR DE BRAF (VEMURAFENIB) EN PACIENTES CON MELANOMA CUTÁNEO NO RESECABLE (ESTADIO IIIC) O METASTÁSIC O (ESTADIO IV) CON LA MUTACIÓN BRAF V600E/K.

Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE

MEK116513

DIFUSIÓN DEL ANESTÉSICO LOCAL EN EL ESPACIO PARAVERTEBRAL TORÁCICO TRAS BLOQUEO PARAVERTEBRAL: ESTUDIO CON TOMOGRAFÍA COMPUTERIZADA CONE BEAM.

Investigador Principal: NURIA GARCÍA GREGORIO

NUR-ROP-2015-01

Cita

Compartir